Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Verrica Pharmaceuticals
Deal Size : $29.5 million
Deal Type : Collaboration
Verrica Announces Amendment to Collaboration and License Agreement with Torii
Details : The agreement aims to initiate a global pivotal Phase 3 clinical trial of Verrica’s product, Ycanth (cantharidin), for the treatment of common warts.
Product Name : Ycanth
Product Type : Other Small Molecule
Upfront Cash : $11.5 million
July 01, 2025
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Verrica Pharmaceuticals
Deal Size : $29.5 million
Deal Type : Collaboration
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Shionogi
Deal Size : $1,050.0 million
Deal Type : Acquisition
Shionogi to buy Japan Tobacco's Unit Torii Pharmaceutical for $1 billion
Details : The two companies would strengthen its domestic business by strengthening sales and marketing channels in dermatology including Vtama (tapinarof), paediatrics, and otolaryngology.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 07, 2025
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Shionogi
Deal Size : $1,050.0 million
Deal Type : Acquisition
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Verrica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Torii Files NDA in Japan for TO-208 in Molluscum Contagiosum
Details : TO-208 previously known as VP-102 is a single-use drug device combination product containing (cantharidin) topical solution. It is being evaluated for the treatment of Molluscum Contagiosum.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Verrica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Verrica Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Verrica Amends Collaboration with Torii to Fund Phase 3 Trial for YCANTH®
Details : Through the licensing agreement with Torii Pharmaceutical, to jointly conduct a global pivotal Phase 3 clinical trial studies of Ycanth (cantharidin) for the treatment of common warts.
Product Name : Ycanth
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 15, 2024
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Verrica Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : NAC-GED-0507
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Nogra Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 26, 2023
Lead Product(s) : NAC-GED-0507
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Nogra Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Verrica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
Product Name : Ycanth
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2022
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Verrica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berotralstat HCl
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : BioCryst Pharmaceuticals
Deal Size : $15.0 million
Deal Type : Collaboration
Details : Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
Product Name : Orladeyo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 14, 2021
Lead Product(s) : Berotralstat HCl
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : BioCryst Pharmaceuticals
Deal Size : $15.0 million
Deal Type : Collaboration
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Verrica Pharmaceuticals
Deal Size : $69.5 million
Deal Type : Licensing Agreement
Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical for VP-102
Details : Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted adm...
Product Name : Ycanth
Product Type : Other Small Molecule
Upfront Cash : $11.5 million
March 17, 2021
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Verrica Pharmaceuticals
Deal Size : $69.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Verrica Pharmaceuticals
Deal Size : $70.0 million
Deal Type : Agreement
Details : The agreement grants Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.
Product Name : Ycanth
Product Type : Other Small Molecule
Upfront Cash : $11.5 million
May 08, 2020
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Verrica Pharmaceuticals
Deal Size : $70.0 million
Deal Type : Agreement
Lead Product(s) : Berotralstat HCl
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : BioCryst Pharmaceuticals
Deal Size : $42.0 million
Deal Type : Agreement
BioCryst Submits Japanese NDA for Oral, Once Daily Berotralstat
Details : Torii Pharmaceutical will pay tiered royalties of up to 40 percent of Japanese net sales of berotralstat to BioCryst upon receipt of a reimbursement price approval NHI Japan.
Product Name : Orladeyo
Product Type : Other Small Molecule
Upfront Cash : $22.0 million
March 02, 2020
Lead Product(s) : Berotralstat HCl
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : BioCryst Pharmaceuticals
Deal Size : $42.0 million
Deal Type : Agreement